Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I randomised, double-blind, parallel-group, placebo-controlled, multiple dose ascending study of CK 2127107 in healthy volunteers

Next Previous
Search
Trial Profile

A Phase I randomised, double-blind, parallel-group, placebo-controlled, multiple dose ascending study of CK 2127107 in healthy volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 12 Apr 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Reldesemtiv (Primary)
  • Indications Muscular atrophy
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Cytokinetics

    • Most Recent Events

    • 30 Nov 2017 According to a Cytokinetics media release, results from this and two other studies (profiles 700242741 and 700247918) are published in Muscle & Nerve Journal "CK-2127107 Amplifies Skeletal Muscle Response to Nerve Activation in Humans".
    • 19 Jun 2015 According to a Cytokinetics media release, results from this and two other studies (profiles 700242100 and 700247918) were presented at the 19th International SMA (Spinal Muscular Atrophy) Researcher Meeting held during the 2015 Annual SMA Conference.
    • 13 Oct 2014 Results published in the Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top